← back to search

Amina Zoubeidi

Cervantes Institute ·
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Prostate Cancer Treatment and Research, Cancer, Lipids, and Metabolism, Estrogen and related hormone effects, and Heat shock proteins research.
h-index
60
citations
11,286
works
552
NIH funding
primary concept
email

Recent publications

Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation
Cancer Cell 2025cited by 16position: middledoi
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
Cell Reports Medicine 2024cited by 28position: middledoi
Abstract 6574: UCHL1 is a molecular indicator and a therapeutic target for neuroendocrine carcinomas
Cancer Research 2024cited by 0position: middledoi
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer
Cell Reports 2023cited by 28position: middledoi
Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase
Cancer Research 2023cited by 14position: middledoi
Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence
Cancer Discovery 2022cited by 85position: middledoi
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Cancer Research 2022cited by 65position: middledoi
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Nature Communications 2021cited by 168position: middledoi
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
Nature Cell Biology 2021cited by 159position: lastdoi
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer
Nature Communications 2021cited by 104position: middledoi
CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer
Nature Communications 2021cited by 64position: middledoi
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer
Nature Communications 2021cited by 35position: middledoi
The DNA methylation landscape of advanced prostate cancer
Nature Genetics 2020cited by 349position: middledoi
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1
Proceedings of the National Academy of Sciences 2020cited by 143position: middledoi
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
Nature Communications 2020cited by 87position: middledoi
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Clinical Cancer Research 2019cited by 388position: middledoi
ONECUT2 is a driver of neuroendocrine prostate cancer
Nature Communications 2019cited by 241position: middledoi
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Cell 2018cited by 742position: middledoi
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Nature Reviews Urology 2018cited by 430position: lastdoi
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19
Cell 2018cited by 313position: middledoi
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
GigaScience 2018cited by 78position: middledoi
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
European Urology 2017cited by 128position: middledoi
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Cancer Research 2017cited by 102position: middledoi
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
Cancer Discovery 2016cited by 440position: lastdoi
Clusterin as a therapeutic target
Expert Opinion on Therapeutic Targets 2016cited by 154position: lastdoi
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Cell Reports 2015cited by 299position: middledoi
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer
The Journal of Pathology 2012cited by 195position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Himisha Beltran · Harvard University4 papers (2016–2020)Paul C. Boutros · University of Virginia3 papers (2017–2023)Dong Lin · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2016–2018)Yuzhuo Wang · China Agricultural University2 papers (2016–2018)Yi Liang · Jimei University2 papers (2017–2018)Junjie T. Hua · Sun Yat-sen University2 papers (2017–2018)Fraser Soares · University Health Network2 papers (2017–2018)Elai Davicioni · Coherus BioSciences (United States)2 papers (2017–2018)Mandeep Takhar · NewYork–Presbyterian Hospital2 papers (2017–2018)Felix Y. Feng · Polytechnique Montréal2 papers (2017–2018)Mark A. Rubin · Praxis2 papers (2016–2018)Nicholas Erho · NewYork–Presbyterian Hospital2 papers (2017–2018)Musaddeque Ahmed · Hospital for Sick Children2 papers (2017–2018)Colin C. Collins · University of British Columbia2 papers (2016–2018)Housheng Hansen He · University Health Network2 papers (2017–2018)Alexander W. Wyatt · Prevention of Organ Failure2 papers (2016–2018)Haiyang Guo · Shandong University2 papers (2017–2018)Alastair Davies · Pfizer (United States)2 papers (2016–2018)Theodorus van der Kwast · Collaborative Group (United States)2 papers (2017–2018)Martin Gleave · Prostate Cancer Canada2 papers (2016–2018)